Novo Nordisk Debuts Wegovy Weight-Loss Treatment in UAE Market

Novo Nordisk has officially released its weight-loss medication, Wegovy, in the United Arab Emirates. The launch marks the first availability of the high-demand semaglutide injection in the Gulf region, targeting a market with some of the highest obesity rates globally. Clinical Efficacy and Regulatory Approval Wegovy, a GLP-1 receptor agonist, is approved by the UAE Ministry of Health and Prevention (MoHAP) for chronic weight management. The treatment is indicated for adults with a Body Mass Index (BMI) of 30 or greater, or a BMI of 27 or greater for individuals with weight-related conditions such as hypertension or type 2 diabetes. Clinical trial data indicates that patients using the once-weekly 2.4mg injection lost an average of 15% of their body weight over 68 weeks when paired with lifestyle interventions. The medication operates by mimicking a hormone that targets areas of the brain that regulate appetite and food intake. Unlike earlier formulations of semaglutide used primarily for diabetes management, Wegovy is specifically branded and dosed for weight loss. Market Demand and Supply Constraints The UAE launch occurs amid a global shortage of GLP-1 medications. Novo…